Share
Dr. Lilly Xu
Medicilon, a leading preclinical contract research organization (CRO), has appointed Dr. Lilly Xu as its Chief Technology Officer (CTO). With over 30 years of experience in early drug discovery and development, Dr. Xu will spearhead technological innovation and global expansion, strengthening Medicilon’s R&D capabilities.
Dr. Xu earned her Ph.D. in Biology from St. Louis University and is recognized as a pioneer in human hepatocyte isolation, metabolism, and drug-drug interactions (DDI). She has successfully led multiple global drug development programs from early discovery through clinical stages, holding leadership roles at Amgen, Sanofi, and other major pharmaceutical and biotech firms.
With this strategic appointment, Medicilon continues to enhance its discovery research platforms, including chemistry, biologics, and pharmacology, reinforcing its position as a leader in preclinical drug discovery and development.
